(Q40976856)

25 September 2017

1 reference

title

Immunotherapy for childhood asthma: is there a rationale for its use? (English)

1 reference

25 September 2017

1 reference

Sigman K

1

1 reference

25 September 2017

Mazer B

series ordinal

2

1 reference

25 September 2017

publication date

1 April 1996

1 reference

Annals of Allergy, Asthma & Immunology

25 September 2017

published in

1 reference

25 September 2017

volume

76

1 reference

25 September 2017

issue

4

1 reference

25 September 2017

page(s)

299-305; quiz 305-9

1 reference

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

1 reference

7 January 2021

Immunotherapy in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Altered production of histamine-releasing factor (HRF) activity and responsiveness to HRF after immunotherapy in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Responses to ragweed-pollen nasal challenge before and after immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Failure of hyposensitisation in treatment of children with grass-pollen asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II. In vitro results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Allergen immunotherapy in asthma: evidence for efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Specific immunotherapy in asthma: is it effective?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

The appropriate use of skin testing and allergen immunotherapy in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

A prospective study on the safety of immunotherapy in children with severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

The hazard of mould hyposensitization in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Decreased production of interleukin-2 receptors after immunotherapy to house dust

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960029-4

7 January 2021

10.1016/S1081-1206(10)60029-4

Identifiers

DOI

1 reference

25 September 2017

1 reference